Hansa Biopharma AB (publ) 24H.F Stock
Hansa Biopharma AB (publ) Price Chart
Hansa Biopharma AB (publ) 24H.F Financial and Trading Overview
| Hansa Biopharma AB (publ) stock price | 3.34 EUR |
| Previous Close | 4.16 EUR |
| Open | 4.03 EUR |
| Bid | 4.11 EUR x 0 |
| Ask | 4.24 EUR x 0 |
| Day's Range | 4.03 - 4.03 EUR |
| 52 Week Range | 3.67 - 9.29 EUR |
| Volume | 3.21K EUR |
| Avg. Volume | 57 EUR |
| Market Cap | 232.64M EUR |
| Beta (5Y Monthly) | 0.965134 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.38 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
24H.F Valuation Measures
| Enterprise Value | 217.64M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.6929767 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Hansa Biopharma AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.965134 |
| 52-Week Change | -10.36% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.29 EUR |
| 52 Week Low | 3.67 EUR |
| 50-Day Moving Average | 4.34 EUR |
| 200-Day Moving Average | 4.89 EUR |
24H.F Share Statistics
| Avg. Volume (3 month) | 57 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 52.44M |
| Float | 39.59M |
| Short Ratio | N/A |
| % Held by Insiders | 8.15% |
| % Held by Institutions | 36.63% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 75.14% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.61% |
| Return on Equity (ttm) | -129.085% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | -20.10% |
| Gross Profit (ttm) | 116.05M EUR |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | -1.16 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | 198.81 EUR |
| Current Ratio (mrq) | 5.784 |
| Book Value Per Share (mrq) | 1.495 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Hansa Biopharma AB (publ)
| Country | Germany |
| State | N/A |
| City | Lund |
| Address | ScheelevAegen 22 |
| ZIP | 223 63 |
| Phone | 46 46 16 56 70 |
| Website | https://www.hansabiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 159 |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Q&A For Hansa Biopharma AB (publ) Stock
What is a current 24H.F stock price?
Hansa Biopharma AB (publ) 24H.F stock price today per share is 3.34 EUR.
How to purchase Hansa Biopharma AB (publ) stock?
You can buy 24H.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Hansa Biopharma AB (publ)?
The stock symbol or ticker of Hansa Biopharma AB (publ) is 24H.F.
Which industry does the Hansa Biopharma AB (publ) company belong to?
The Hansa Biopharma AB (publ) industry is Biotechnology.
How many shares does Hansa Biopharma AB (publ) have in circulation?
The max supply of Hansa Biopharma AB (publ) shares is 66.39M.
What is Hansa Biopharma AB (publ) Price to Earnings Ratio (PE Ratio)?
Hansa Biopharma AB (publ) PE Ratio is now.
What was Hansa Biopharma AB (publ) earnings per share over the trailing 12 months (TTM)?
Hansa Biopharma AB (publ) EPS is -1.38 EUR over the trailing 12 months.
Which sector does the Hansa Biopharma AB (publ) company belong to?
The Hansa Biopharma AB (publ) sector is Healthcare.